Electrochemical characterization of repaglinide and its determination in human plasma using liquid chromatography with dual-channel coulometric detection

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 878, Issue 31, 2010, Pages 3243-3248

  Jirovský, David ^a   Bartošová, Zdenka ^a   Skopalová, Jana ^a   Maier, Vítezslav ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Coulometric detection; HPLC; Peroral antidiabetics; Plasma; Repaglinide; Rosiglitazone

Indexed keywords

COULOMETRIC DETECTION; HPLC; PERORAL ANTIDIABETICS; REPAGLINIDE; ROSIGLITAZONE;

COULOMETERS; ESTERS; LIQUIDS; PHOSPHORIC ACID; PLASMA (HUMAN); PLASMAS;

LIQUID CHROMATOGRAPHY;

ACETIC ACID ETHYL ESTER; ACETONITRILE; DISODIUM HYDROGEN PHOSPHATE; PHOSPHORIC ACID; REPAGLINIDE;

ARTICLE; CALIBRATION; COULOMETRY; DRUG BLOOD LEVEL; DRUG DETERMINATION; HUMAN; PH; PRIORITY JOURNAL; REVERSED PHASE LIQUID CHROMATOGRAPHY;

CARBAMATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORIMETRY; ELECTROCHEMICAL TECHNIQUES; HUMANS; HYDROGEN-ION CONCENTRATION; HYPOGLYCEMIC AGENTS; LINEAR MODELS; PIPERIDINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THIAZOLIDINEDIONES;

EID: 78449280606     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2010.09.029     Document Type: Article

References (25)

1. Diabetes, Atlas 2007, International Diabetes Federation, (2010 January) IDF Website [Online] http://www.idf.org. third ed.
2. Koopman R.J., Mainous A.G., Diaz V.A., Geesey M.E. Ann. Fam. Med. 2005, 3:60-63.
3. Johansen O.E., Birkelan K.L. Am. J. Cardiovasc. Drugs 2007, 7:319-335.
4. Ambavane V., Patil R., Ainapure S.S. J. Postgraduate Med. 2002, 48:246-248.
5. Plosker G.L., Figgitt D.P. Pharmacoeconomics 2004, 22:389-411.
6. Mandid Z., Gabelica V. J. Pharm. Biomed. Anal. 2006, 41:866-871.
7. El-Ries M.A.N., Mohamed G.G., Attia A.K. Yakugaku Zasshi 2008, 128:171-177.
8. Mark M., Grell W. Br. J. Pharmacol. 1997, 121:1597-1604.
9. Wolffenbuttel B.H. Neth. J. Med. 1999, 55:209-211.
10. Oliver S., Windfeld K., Hatorp V. Diabetes 1997, 46:1263-11263.
11. Hatorp V. Clin. Pharmacokinet. 2002, 41:471-483.
12. Owens D.R. Diabetic Med. 2004, 15:S28-S36.
13. Hatorp V., Oliver S., Su C.A. Int. J. Clin. Pharmacol. Ther. 1998, 36:636-641.
14. Plum A., Müller L.K., Jansen J.A. Methods Find. Exp. Clin. Pharmacol. 2000, 22:139-143.
15. Ho E.N.M., Yiu K.C.H., Wan T.S.M., Stewart B.D., Watkins K.L. J. Chromatogr. B 2004, 811:65-73.
16. Venkatesh P., Harisudhan T., Choudhury H., Mullangi R., Srinivas N.R. Biomed. Chromatogr. 2006, 20:1043-1048.
17. Maier V., Znaleziona J., Jirovsky D., Skopalova J., Petr J., Sevcik J. J. Chromatogr. A 2009, 1216:4492-4498.
18. Özkan S.A. Chromatographia 2007, 66:S3-313.
19. Svendsen C.N. Analyst 1993, 118:123-129.
20. Acworth I.N., Gamache P.H. Am. Lab. 1996, 28:33-37.
21. Greischel A., Beschke K., Rapp H., Roth W. J. Chromatogr. B 1991, 568:246-252.
22. ICH Harmonised Tripartite Guideline: Validation of Analytical Procedures Q2 (R1), Step 4 version, November 2005.
23. Ruzilawati A.B., Wahab M.S.A., Imran A., Ismail Z., Gan S.H. J. Pharm. Biomed. Anal. 2007, 43:1831-1835.
24. Polson C., Sarkar P., Incledon B., Raguvaran V., Grant R. J. Chromatogr. B 2003, 785:263-275.
25. Wagstaff A.J., Goa K.L. Drugs 2002, 62:1805-1837.